MedTrace Logo

Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

NCT05191342 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2022-01-13

No results posted yet for this study

Summary

Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.

Conditions

  • PCSK9

Interventions

DIAGNOSTIC_TEST

Enzyme-linked immunosorbent assay for PCSK9

Enzyme-linked immunosorbent assay for plasma PCSK9

Sponsors & Collaborators

  • First Affiliated Hospital of Harbin Medical University

    lead OTHER

Principal Investigators

  • Yue Li, Doctor · First Affiliated Hospital of Harbin Medical University

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-01
Primary Completion
2022-11-01
Completion
2022-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05191342 on ClinicalTrials.gov